rc-18

Telitacicept (RC18) 是一种全人源TACI-Fc融合蛋白，兼具BLyS和APRIL抑制作用，有效阻断B淋巴细胞增殖，适用于B细胞自身免疫性疾病研究。

Corrector C18 is a class I mutation corrector which rescues CFTR mutations in nucleotide-binding domain 1 (NBD1) by modulating proteostasis.

ARC 186 是一种核酸适配体，是高效的补体抑制剂，通过阻断转化酶催化的C5 激活发挥作用。

NH2-C6-ARC186是带有NH2-C6接头的ARC186衍生物，可用于与其他肽或分子偶联。它作为一种适体，是一种高效的补体抑制剂，通过抑制转化酶催化的C5活化发挥作用。

GPX4-IN-18 (Compound 17) 是一种含有二茂铁结构的谷胱甘肽过氧化物酶 4 (GPX4) 抑制剂，也是铁死亡的诱导剂。该化合物可以在 OS-RC-2 透明细胞肾细胞癌细胞中增加 ROS 的产生和丙二醛 (MDA) 的水平。GPX4-IN-18 能诱导 HT-1080 细胞发生铁死亡，其 IC50 分别为 0.007 μM (无铁抑制剂-1) 和 1.486 μM (有铁抑制剂-1)。此外，GPX4-IN-18 可降低 OS-RC-2 异种移植小鼠模型中的肿瘤体积及肿瘤内 GPX4 含量。

Neuromedin C is a bombesin-like neuropeptide that stimulates uterine smooth muscle contraction and the release of gastrin , somatostatin, and amylase in rats. Neuromedin C is a truncated form of gastrin-releasing peptide corresponding to the GRP amino acids 18-27. It inhibits GRP and bombesin binding to rat pancreatic membranes (IC50s = 0.4 and 2.2 nM, respectively), which can be reduced by sodium chloride and guanylyl imidodiphosphate . Neuromedin C induces scratching and mast cell degranulation in mice when administered intradermally at doses ranging from 1 to 300 nmol/site, which is inhibited by the BB2 bombesin receptor agonist RC-3095 and reduced in mast cell-deficient mice. Neuromedin C (3.2 nmol/kg, i.p.) reduces rat glucose consumption by approximately 50% for up to one hour.